Ivermectin within the treatment protocol for COVID-19 in Peru: Use without scientific evidence
DOI:
https://doi.org/10.20453/stv.v8i1.3789Abstract
Ivermectin is one of the most widely used antiparasitic drugs in veterinary medicine. Moreover, it is used for treating many parasitosis in human medicine. However, its uncontrolled massive use is being associated to the appearance of parasitic resistance. The emergence of SARS-CoV-2, causing agent of COVID-19, has challenged health systems worldwide, forcing them to urgently work in the development of proper therapeutic protocols against such disease. In Peru, the Ministry of Health approved the addition of ivermectin within the treatment protocol for COVID-19. Aiming to collect scientific evidence that supported such decision, a systematic search was performed within scientific journals´ digital repositories and clinical trials´ databases focused on therapy against COVID-19. Until the date of submission of this article, no scientific evidence was found to support the efficacy or safety of using ivermectin as treatment against SARS-CoV-2 in humans. Solely an in vitro study was found as suggestive evidence, but its replication in people would be unlikely as it would be necessary to administer considerably higher doses of the drug than those approved for use in humans. Additionally, some clinical trials are currently assessing the addition of ivermectin in COVID-19 patients, but their results have not been published yet. Finally, this article describes both the possible consequences of the generalized misinformation regarding the use of ivermectin against COVID-19 added to the permissibility for using veterinary products containing such drug in human patients, as well as the important role of veterinarians in this situation.
Published
How to Cite
Issue
Section
License
All articles published in Salud y Tecnología Veterinaria are under a Creative Commons Reconocimiento 4.0 International license.
The authors retain the copyright and grant the journal the right of first publication, with the work registered with the Creative Commons License, which allows third parties to use what is published whenever they mention the authorship of the work, and to the first publication in this magazine.
Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version published in this journal, provided they clearly indicate that the work was published in this journal.
The authors can file in the repository of their institution:
The research work or thesis of degree from which the published article derives.
The pre-print version: the version prior to peer review.
The Post-print version: final version after peer review.
The definitive version or final version created by the publisher for publication.
